EGFR mutations, including point mutations and small insertions/deletions, were the first identified pharmaceutically targetable mutations in NSCLC and remain the most widely used predictive biomarker for EGFR tyrosine kinase inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.